Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2008

View Archived Issues

BrainStorm reports results from rat study of NTF cells in Parkinson's disease

Novartis pays USD 25 million milestone payment to Antisoma in relation to ASA-404

4SC acquires stake in Nexigen and enters licensing agreement with ViroLogik

InSite signs Chinese licensing agreement with Essex Biotechnology for AzaSite

Human Genome Sciences presents an update on clinical development portfolio

Gene therapy for retinal albinism presented at the ASGT meeting

Murine von Willebrand disease ameliorated by helper-dependent adenovirus gene transfer

Boehringer Ingelheim gets first approval within E.U. for Actilyse

Antiinflammatory compound ND-07 improves experimental acute pancreatitis

Bristol-Myers Squibb to acquire cancer therapeutics company, Kosan Biosciences

FDA grants fast track to Wyeth's 13-valent pneumococcal conjugate vaccine

IntelGenx presents positive results from pilot pharmacokinetic study on CPI-300

Lipoxen reports phase I data for long-acting insulin candidate, SuliXen

SymBio completes enrollment in phase II study in indolent non-Hodgkin's lymphoma

Triphendiol safe in phase Ia pharmacokinetic study

Wyeth receives FDA approvable letter for Tygacil in community-acquired pneumonia

Phase I data show activity of NKTR-102 in solid tumor patients

Camurus reports positive phase II results for CAM-2028 in oral mucositis pain

Human Genome Sciences has initiated dosing in phase I HGS-1029

Novel antiinfective agents disclosed in recent GSK patents

Novel anti-HIV agents reported in recent patents

Nisshin Kyorin patent describes new therapeutic options for IBD

Genmab announces completion of pivotal phase III trial of ofatumumab in CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...